



Nanomedicine & Immunotherapy: The Grail for Cancer Treatment?

Guest Editors:

Dr. Cátia Domingues

Dr. Ana Figueiras

Dr. Ivana Jarak

Deadline for manuscript
submissions:

closed (30 September 2024)

Message from the Guest Editors

Cancer continues to represent a significant socio-economic and health problem worldwide. Despite the advances in diagnosis and treatment, most patients do not respond to or become resistant to conventional treatments or relapse. The advent of immunotherapy has encouraged patient-targeted treatment. However, some gaps in knowledge remain, namely cancer immune editing/exhaustion issues and adverse immunotoxicity events. Therefore, combining conventional therapies with nanomedicine has gained ground in the scientific community. Nanomedicine explores the potential of applying nanotechnology to medicine via triggering the release of cargos, such as imaging and therapeutic agents, for cancer-patient-personalized diagnosis, treatment, and monitoring. Consequently, merging immunotherapy and nanomedicine may constitute a direction for improving cancer diagnosis and treatment, focusing on cancer cells and the surrounding tumor microenvironment.

Hence, cordially invite researchers to submit original research or review manuscripts that present up-to-date data on immunotherapy and nanomedicine applications for cancer prevention and management.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)